TISIDB

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Cell projection, dendrite Cell junction, synapse, synaptosome Note=Enriched in synaptoneurosomes (By similarity). Shuttles between the nucleus and the cytoplasm in a CRM1-dependent manner. Colocalizes throughout the cytoplasm in granules with polyadenylated RNAs, PABPC1 and STAU1. Also frequently colocalizes in cytoplasmic stress granule-like foci with ELAVL1, TIA1 and TIAL1.
Domain	PF00536 SAM domain (Sterile alpha motif)
Function	Acts as a translational repressor of SRE-containing messengers.

> Gene Ontology [ TOP ]
Biological Process	GO:0000288 nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay GO:0000289 nuclear-transcribed mRNA poly(A) tail shortening GO:0000956 nuclear-transcribed mRNA catabolic process GO:0006401 RNA catabolic process GO:0006402 mRNA catabolic process GO:0006417 regulation of translation GO:0010608 posttranscriptional regulation of gene expression GO:0017148 negative regulation of translation GO:0019439 aromatic compound catabolic process GO:0034248 regulation of cellular amide metabolic process GO:0034249 negative regulation of cellular amide metabolic process GO:0034250 positive regulation of cellular amide metabolic process GO:0034655 nucleobase-containing compound catabolic process GO:0043487 regulation of RNA stability GO:0043488 regulation of mRNA stability GO:0044270 cellular nitrogen compound catabolic process GO:0045727 positive regulation of translation GO:0046700 heterocycle catabolic process GO:1901361 organic cyclic compound catabolic process
Molecular Function	GO:0003729 mRNA binding GO:0030371 translation repressor activity GO:0045182 translation regulator activity
Cellular Component	GO:0000932 cytoplasmic mRNA processing body GO:0030425 dendrite GO:0035770 ribonucleoprotein granule GO:0036464 cytoplasmic ribonucleoprotein granule

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SAMD4A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SAMD4A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SAMD4A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.322	0.241
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.363	0.796
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.298	0.754
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.279	0.532
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.588	0.786
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.112	0.968
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.329	0.387
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.257	0.874
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-1.013	0.582
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.151	0.881
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.123	0.395
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.466	0.000428

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SAMD4A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	1.4	13.4	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	1.7	13.1	0.032
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	11.8	-11.8	0.193
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SAMD4A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SAMD4A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SAMD4A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SAMD4A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SAMD4A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SAMD4A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SAMD4A
Name	sterile alpha motif domain containing 4A
Aliases	KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location	14q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SAMD4A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SAMD4A